Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAkari Therapeutics announces 1-for-40 reverse split to address Nasdaq delisting risk
Filed March 17, 2026 · Period ending March 17, 2026 · ~1 min read
Key Changes
-
high
Company implementing 1-for-40 reverse split of ADSs effective March 31, reducing outstanding shares by 97.5% to boost per-share price and meet Nasdaq's minimum bid requirement.
Item 8.01 view on EDGAR → -
high
Akari explicitly warns it cannot guarantee the reverse split will achieve or maintain Nasdaq compliance, indicating significant delisting risk remains even after the split.
Item 8.01 view on EDGAR → -
medium
The reverse split changes ADS ratio from 1:2,000 to 1:80,000 ordinary shares but does not affect underlying ordinary shares or total company ownership structure.
Item 8.01 view on EDGAR →
Summary
Akari Therapeutics disclosed a 1-for-40 reverse split of its American Depositary Shares, effective March 31, 2026, designed to increase the per-share trading price and address Nasdaq's minimum bid price requirement. The action consolidates every 40 ADSs into one, reducing the share count by 97.5% while proportionally increasing the price per share. Critically, the company cannot guarantee this maneuver will succeed in maintaining Nasdaq compliance, signaling the stock is currently trading below the $1.00 minimum and faces potential delisting.
Retail investors should understand that reverse splits do not change the fundamental value of their holdings—a shareholder with 400 ADSs worth $100 will own 10 ADSs still worth $100 after the split. However, the company's explicit warning about ongoing compliance uncertainty suggests deeper liquidity or business challenges. Watch for Nasdaq compliance updates in the coming weeks and monitor whether the post-split price can sustain above $1.00, as failure would likely trigger delisting proceedings.
Section-by-Section Diff
Event · Item 3.03 — Material Modification to Rights of Security Holders
Item 3.03 — Material Modification to Rights of Security Holders filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Although the market price per ADS is expected to increase proportionally, the Company can give no assurance that the Ratio Change will result in the Company satisfying and maintaining the minimum bid price requirement of Nasdaq.
The company explicitly states it cannot guarantee the reverse split will achieve or maintain Nasdaq's minimum bid price requirement. This disclosure indicates the company is at risk of delisting if the reverse split fails to bring the ADS price into compliance, and suggests the stock price may be trading below $1.00 per share currently.
Event · Item 7.01 — Regulation FD Disclosure
Akari Therapeutics announced a Ratio Change via press release on March 17, 2026.
Added in current filing · verify on EDGAR →
On March 17, 2026, the Company issued a press release announcing the Ratio Change.
The company disclosed a 'Ratio Change' through a press release. The 8-K does not specify what this ratio change entails (e.g., reverse stock split, conversion ratio adjustment, or other corporate action). The press release itself (Exhibit 99.1) is referenced but not included in the body text provided, so the nature and investor impact of the ratio change cannot be determined from this filing excerpt alone.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The information set forth in this Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.
The disclosure is made under Item 7.01 (Regulation FD Disclosure), meaning the information is 'furnished' rather than 'filed.' This distinction means the company has lower legal liability for the disclosed information and it will not be automatically incorporated by reference into other SEC filings. This is standard practice for voluntary disclosures under Regulation FD.
Event · Item 9.01 — Financial Statements and Exhibits
Akari Therapeutics filed an 8-K attaching a press release dated March 17, 2026; no material business event disclosed in filing body.
Added in current filing · verify on EDGAR →
99.1
Press release dated March 17, 2026.
The company attached a press release dated March 17, 2026 as Exhibit 99.1. The 8-K body provides no details about the press release content, so the nature and materiality of any disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify